VEGF启动子介导双自杀基因重组腺病毒对LoVo细胞的体外杀伤作用

南方医科大学学报 ›› 2005, Vol. 25 ›› Issue (05): 521-523.

VEGF启动子介导双自杀基因重组腺病毒对LoVo细胞的体外杀伤作用

黄宗海, 陈建雄, 苏国强

南方医科大学珠江医院普通外科, 广东, 广州, 510282

出版日期:2005-05-20 发布日期:2005-05-20
基金资助:
收稿日期:2005-3-1。
基金项目:国家863计划生物和现代农业科技研究基金项目(2001AA217171);广东省自然科学基金重点项目(013072)
作者简介:黄宗海(1954- ),男,第一军医大学珠江医院普通外科主任,教授,博士生导师,电话:020-61643213

In vitro antitumor effect of adenovirus containing CD-TK fusion gene driven by VEGF promoter on LoVo cells

HUANG Zong-hai, CHEN Jian-xiong, SU Guo-qiang

南方医科大学珠江医院普通外科, 广东, 广州, 510282

Online:2005-05-20 Published:2005-05-20

摘要/Abstract

摘要： 目的探讨VEGF启动子驱动的CD/TK双自杀基因重组腺病毒(Ad-VEGFP-CDglyTK)对大肠癌LoVo细胞的体外杀伤作用.方法分别用重组腺病毒Ad-VEGFp-CDglyTK、Ad-CMV-CD、Ad-CMV-TK、Ad-CMV-CDglyTK转染大肠癌LoVo细胞,给予前药5-FC、GCV,测定LoVo细胞的集落形成、细胞存活率及该治疗系统的旁观者效应.结果与Ad-CMV-CD、Ad-CMV-TK相比,Ad-VEGFp-CDglyTK系统对LoVo细胞的集落形成、细胞生长均具有更强抑制作用,并可见较明显的旁观者效应.而与CMV启动子的双自杀基因相比,其作用无显著性差异.结论 VEGF启动子驱动的双自杀基因治疗系统对大肠癌LoVo细胞有确切的杀伤作用,其作用强度与强启动子CMV驱动的双自杀基因治疗系统相似.

Abstract: Objective To evaluate the in vitro antitumor effect of adenovirus containing cytosine deaminase (CD) and thymine kinase (TK) gene driven by vascular endothelial growth factor (VEGF) promoter (Ad-VEGFp-CDglyTK) on human colorectal cancer LoVo cells.Methods The adenoviral vectors Ad-VEGFp-CDglyTK, Ad-CMV-CD, Ad-CMV-TK and Ad-CMV- CDglyTK were transfected into LoVo cells, which were then treated with the prodrugs 5-FC or GCV to observe the plating efficiency and growth inhibition effect and bystander effect of the vectors on LoVo cells.Results Compared with the two vectors containing single suicide gene, Ad-VEGFp-CDglyTK showed more remarkable inhibitory effect on the plating efficiency and growth of the tumor cells, and the bystander effect of the fusion suicide gene was much stronger than that produced by single suicide gene. But the LoVo cells infected with Ad-VEGFp-CDglyTK exhibited similar sensitivity to the prodrugs with the cells infected with Ad-CMV-CDglyTK.Conclusion Ad-VEGFp-CDglyTK has potent antitumor effect on LoVo cells in vitro, which is comparable with the effect of Ad-CMV-CDglyTK.

中图分类号:

R730.59

黄宗海, 陈建雄, 苏国强. VEGF启动子介导双自杀基因重组腺病毒对LoVo细胞的体外杀伤作用[J]. 南方医科大学学报, 2005, 25(05): 521-523.

HUANG Zong-hai, CHEN Jian-xiong, SU Guo-qiang. In vitro antitumor effect of adenovirus containing CD-TK fusion gene driven by VEGF promoter on LoVo cells[J]. Journal of Southern Medical University, 2005, 25(05): 521-523.

参考文献

[1] 黄元媛,黄宗海,陈建发,等.新法制备含VEGF启动子驱动的CD/TK融合基因重组腺病毒[J] 第一军医大学学报,2004,24(1):117-20.Huang YY, Huang ZH, Chen JF, et al. An easier method for generating recombinant adenovirus containing CD/TK fusion gene driven by the vascular endothelial growth factor promoter [J]. J First Mil Med Univ/Di Yi Jun Yi Da Xue Xue Bao, 2004, 24(1): 117-20.
[2] 陈建发,黄宗海,俞金龙,等.含血管内皮生长因子启动子驱动TK自杀基因重组腺病毒的制备及其体外杀伤作用观察[J].第一军医大学学报,2004,24(6):623-7.Chen JF, Huang ZH, Yu JL, et al. Construction of recombinant adenoviruses containing cytosine deaminase gene driven by the vascular endothelial growth factor promoter using an AdEsier-1 system [J]. J First Mil Med Univ/Di Yi Jun Yi Da Xue Xue Bao,2004, 24(6): 623-7.
[3] Suhardja A, Hoffman H. Role of growth factors and their receptors in proliferation ofmicrovascular endothelial cells[J]. Microsc Res Tech,2003, 60: 70-5.
[4] Underiner TL, Ruggeri B, Gingrich DE. Development of vascular endothelial growth factor receptor (VEGFR) kinase inhibitors as anti-angiogenic agents in cancer therapy[J]. Curr Med Chem, 2004,11: 731-45.
[5] Qi L, Robinson WA, Brady BM, et al. Migration and invasion of human prostate cancer cells is related to expression of VEGF and its receptors[J]. Anticancer Res, 2003, 23: 3917-22.
[6] 黄宗海,陈治,钱伟峰,等.血管内皮细胞生长因子及其受体在大肠癌组织中的表达[J].第一军医大学学报,2001,21(3):206-8.Huang ZH, Chen Z, Qian WF, et al. Expression of vascular endothelial growth factor and its receptor in colorectal carcinoma [J]. J First Mil Med Univ/Di Yi Jun Yi Da Xue Xue Bao, 2001, 21(3): 206-8.
[7] Nicholas TW, Read SB, Burrows FJ, et al. Suicide gene therapy with herpes simplex virus thymidine kinase and ganciclovir is enhanced with connexins to improve gap junctions and bystander effects [J].Histol Histopathol, 2003, 18(2): 495-507.
[8] Denny WA. Tumor-activated prodrugs-a ew approach to cancer therapy[J]. Cancer Invest, 2004, 22(4): 604-19.